Intellia Therapeutics (NTLA) incurred a loss of $1.10 per share (including one-time expenses of change in fair value of investments) in the first quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.26. In the year-ago quarter, the company had incurred a loss of $1.12 per share.The company’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of $16.6 million for the first quarter of 2025. Revenues declined 42.6% on a year-over-year basi ...